# Cardioselective (β₁) Blockers

## Examples

- **Second generation (β₁-selective):**
  - `atenolol`
  - `metoprolol`
  - `bisoprolol`
  - `acebutolol` _(partial agonist — ISA)_
  - `betaxolol`
  - `esmolol` _(ultrashort-acting, IV only)_
  - `nebivolol` _(also ↑ NO release — vasodilator)_

> They **reduce BP, HR, and mortality** with **less bronchospasm**, making them **preferred** in hypertension and heart failure.

## Mechanism of Action (MOA)

- **Selectively block β₁-adrenoceptors** (mainly in heart and juxtaglomerular apparatus of kidney).
- **↓ HR, ↓ contractility, ↓ AV conduction, ↓ cardiac output**
- **↓ renin release** → ↓ Angiotensin II → ↓ vasoconstriction and aldosterone.
- **Minimal β₂ blockade**, so **less bronchospasm and metabolic interference** than non-selectives (though not zero).
- At **high doses**, selectivity is **lost** → may block β₂ receptors too.

## Pharmacodynamics (Effects)

| System        | Effect                                                 |
| :------------ | :----------------------------------------------------- |
| **Heart**     | ↓ HR, ↓ force, ↓ conduction → ↓ myocardial O₂ demand   |
| **Vessels**   | ↓ BP (mainly by ↓ CO & renin)                          |
| **Kidney**    | ↓ Renin secretion                                      |
| **Lungs**     | Minimal bronchoconstriction (safe in mild asthma/COPD) |
| **Metabolic** | Fewer effects on glucose/lipid metabolism              |

## Pharmacokinetics

| Drug             | Notes                                                                                                      |
| :--------------- | :--------------------------------------------------------------------------------------------------------- |
| **`Atenolol`**   | Water-soluble, low CNS penetration; excreted unchanged in urine; long-acting (1× daily).                   |
| **`Metoprolol`** | Lipophilic, hepatic metabolism (CYP2D6); shorter duration.                                                 |
| **`Bisoprolol`** | Potent, long-acting, reno-hepatic excretion.                                                               |
| **`Acebutolol`** | Has intrinsic sympathomimetic activity (ISA).                                                              |
| **`Esmolol`**    | IV use only; **ultrashort-acting** (half-life ~10 min); useful in acute arrhythmias or intraoperative HTN. |
| **`Nebivolol`**  | Also releases **NO → vasodilation**; long-acting and highly β₁-selective.                                  |

## Indications

- **Hypertension** — preferred β-blockers (esp. `atenolol`, `bisoprolol`, `metoprolol`).
- **Angina pectoris** — ↓ myocardial oxygen demand.
- **Chronic heart failure (HFrEF)** — `bisoprolol`, `metoprolol succinate`, `nebivolol` improve survival.
- **Cardiac arrhythmias** — SVT, rate control in AF, etc.
- **Post-MI secondary prevention.**
- **Thyrotoxicosis**, **migraine**, **aortic dissection**, **tremor[^1]** (as supportive uses).
- **Perioperative control** of BP and HR (`esmolol` IV).

[^1]: Tremor is a neurological condition that includes shaking or trembling movements in one or more parts of the body, most commonly affecting a person's hands

## Adverse Effects

| System             | Effect / Mechanism                                                   |
| :----------------- | :------------------------------------------------------------------- |
| **Cardiovascular** | Bradycardia, hypotension, heart block, heart failure (in high dose). |
| **Respiratory**    | Minimal bronchospasm (but possible in severe asthma).                |
| **CNS**            | Fatigue, sleep disturbances, depression (esp. lipophilic drugs).     |
| **Metabolic**      | May mask hypoglycemia; mild ↑ triglycerides.                         |
| **Withdrawal**     | Rebound tachycardia / hypertension if stopped suddenly.              |

## Cautions

- **Asthma / COPD:** Prefer β₁-selective, but monitor for bronchospasm.
- **Diabetes:** Use cautiously; monitor glucose.
- **Bradycardia, AV block, heart failure:** Dose carefully.
- **Avoid abrupt discontinuation.**

## Contraindications

- **Severe bradycardia / AV block.**
- **Acute decompensated heart failure.**
- **Severe hypotension.**
- **Cardiogenic shock.**
- **Severe asthma (relative).**

## Key Points Summary

| **Feature**          | **β₁-Selective Blockers**                                |
| :------------------- | :------------------------------------------------------- |
| Receptor selectivity | β₁ only (heart & kidney)                                 |
| Effect on BP         | ↓ CO, ↓ renin                                            |
| Effect on lungs      | Minimal bronchospasm                                     |
| Lipid solubility     | Varies (high: `metoprolol`; low: `atenolol`)             |
| Major advantages     | Safe in mild asthma/COPD, diabetics                      |
| Special notes        | `Esmolol` for emergencies; `Nebivolol` adds vasodilation |
